Raltegravir, a novel integrase inhibitor, enhances both phases of HIV decay, researchers report. This "challenges the current understanding of HIV-1 turnover and compartmentalization," they note in the November 12th issue of AIDS. Reuters Health Information
A synthetic peptide derived from a hepatitis C virus (HCV) protein - dubbed "C5A" -- has a unique virucidal mode of action with potent activity that renders HIV and HCV particles noninfectious, according to new research. Reuters Health Information
In dually infected patients, suppression of herpes simplex virus 2 (HSV-2) with acyclovir also has an impact on HIV levels, according to US and Peruvian investigators. Reuters Health Information
Dr. Susan Buchbinder discusses the data on HIV vaccine prevention studies presented at the 15th Conference on Retroviruses and Opportunistic Infections. Medscape HIV/AIDS
Infants with perinatal HIV infection despite single-dose nevirapine therapy respond well to a four-drug/three-class antiretroviral treatment regimen, according to a feasibility study conducted in South Africa. Reuters Health Information
Ribavirin (RBV) exposure is important for maximizing the response to chronic hepatitis C virus therapy. However, RBV-associated haemolytic anaemia may force dose reductions or even treatment discontinuation. Journal of Viral Hepatitis
